Where is your R&D budget leaking value — and where is funding slipping away?
See the current state of your R&D — portfolio health, funding strategy, technology roadmap, and collaboration — in a single picture within two weeks. Not a solution, a clear diagnosis. Delivered fully online.
Our methods come from work governed as an operator inside an international agricultural-equipment OEM — where outcomes were owned, not advised. Founders & full bios →
DiagnosisThe picture first, then the solution
The Diagnostic is an objective assessment. It shows you the real risk and opportunity map of your R&D operation.
It maps out where your problems and opportunities are; how to resolve them is a separate, later step. Most identified actions can be carried out with your own team. The goal is to clarify the picture independently first.
What this service shows
- The health and concentration risk of your R&D portfolio
- Which projects are fundable and which programs match
- The state of your technology roadmap and capability gaps
- Whether existing R&D collaborations are working — and which new ones would close capability gaps
Delivered as separate work
- Grant / funding application writing
- Detailed action or implementation planning
- Project-level feasibility or financial analysis
- Ongoing advisory
Why It's NeededThe visible picture can be clean. The problem is what's invisible.
An R&D organization manages what it can see. The most expensive problems, though, do not show up in the budget — because what is invisible has no trigger. No alarm goes off; the budget line simply reads "in progress." And quietly, it can cost more than all the visible problems combined.
Resource-draining projects
Projects that consume person-months out of inertia, with no strategic return left.
Missed funding
Calls that fit your projects perfectly, opening and closing without ever hitting your radar.
Roadmap blind spots
Capability gaps — AI, autonomy, electrification, digitalization — hidden behind an aging roadmap.
What You ReceiveA single R&D Current-State Assessment Report
A board-ready, scored and prioritized report — and a session where we review it together.
4-Axis Maturity Scorecard (1–5) + Profile
The current state is scored on a 1–5 scale across four axes, with findings and recommended actions for each: R&D Portfolio Health (balance, concentration risk, value vs. resource drain), Funding Strategy (fundable projects, matching national, EU and EUREKA programmes, and timing across the call calendar), Technology Roadmap (current state, target technologies, and capability gaps), and Collaboration & Partnerships (which university, consortium, and external R&D links are active and value-generating, and which are dormant and should be reactivated or closed).
Top 3 Critical Findings
The three highest-priority risks or opportunities, each flagged with its severity (high / medium) and recommended action — not a scattered list, but what to look at first.
Executive Summary & Recommended Next Steps
An executive summary of the findings; recommended next work and — if useful — its estimated scope, timeline, and budget band. Possible collaboration opportunities are noted here too.
What We Need From YouInputs we review
All data you share is reviewed under a signed Non-Disclosure Agreement (NDA).
- Technology & product roadmapYour 24–36 month development plans
- R&D portfolio summariesTechnical summaries of active / planned projects
- Resource & workforce allocationStaff / project distribution, person-month breakdown
- Funding history & targetsPast applications and the programs you're targeting
ProcessFrom call to report in four steps
Intro call & NDA
We scope it together and sign the NDA.
Data handover
You share roadmap, portfolio and funding inputs.
Review & analysis
Current state mapped across the four axes.
Report + 90-min session
Report delivered and the online review session is held.
TermsFixed scope, transparent pricing
Fixed scope. The scope is set; the fee is determined by the three drivers below.
- Active project count — up to 20 active projects is standard scope; above that, delivery time and fee may increase.
- R&D team scale — standard scope covers up to 50 R&D staff; larger organizations may increase delivery time and fee.
- Delivery mode — fully online by default; on-site visits are arranged at additional cost (travel & accommodation).
Credit: if you move to a comprehensive Luminairo engagement within 30 days, 50% of this fee is credited toward it.
Payment: 100% in advance upon agreement, to reserve the slot.
Delivery: two weeks after complete inputs; fully online (on-site optional, at additional cost).
Who It's ForWho this service is built for
Target profile
Industrial and AgTech R&D organizations with a structured portfolio, an engineering team, and active R&D / funding activity; findings that go to the board.
About the Diagnostic
It is a fixed-scope diagnostic. It maps the current state of your R&D across four dimensions — portfolio health, funding strategy, technology roadmap, and collaboration — in a single picture within two weeks. It is an independent diagnosis that shows where the problems and opportunities are; solutions are a separate step.
The report is delivered two weeks after complete inputs, followed by a closing session. The fee starts at €1,400 + VAT; it is fixed scope, and the price is determined by active project count, R&D team scale, and delivery mode. Standard scope covers up to 20 active projects and 50 R&D staff. The service is delivered fully online; on-site visits are arranged at additional cost.
A single R&D Current-State Assessment Report: a 1–5 maturity scorecard across four axes (R&D Portfolio Health, Funding Strategy, Technology Roadmap, Collaboration & Partnerships) with findings and recommended actions per axis, the top three critical findings, and an executive summary with recommended next steps. It is delivered as a written report plus a 90-minute online executive review session.
Fully online by default — document review, analysis, and the executive review session are all conducted remotely. On-site visits can be arranged when needed, at additional cost (travel and accommodation).
No. The goal is to clarify the picture independently first; most identified actions can be carried out with your own team. If you choose to move to a comprehensive Luminairo engagement within 30 days, 50% of the diagnostic fee is credited toward it.
All shared data is reviewed under a signed Non-Disclosure Agreement (NDA). The main inputs reviewed are your technology and product roadmap, R&D portfolio summaries, resource/workforce allocation, and funding history and targets.
Ready to see the real picture of your R&D portfolio?
Request a short introductory call. We'll scope your inputs together and get back to you within 24 hours, with an NDA draft.
Request an Intro Call